<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40931372</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1943-2704</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Wounds : a compendium of clinical research and practice</Title><ISOAbbreviation>Wounds</ISOAbbreviation></Journal><ArticleTitle>Pulsed electromagnetic field stimulation therapy for Charcot foot ulcer: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>323</StartPage><EndPage>328</EndPage><MedlinePgn>323-328</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.25270/wnds/25002</ELocationID><Abstract><AbstractText Label="BACKGROUND">Charcot foot is a debilitating complication of peripheral neuropathy and is primarily associated with diabetes, leading to structural damage, ulceration, and osteomyelitis. Pulsed electromagnetic field (PEMF) therapy is a promising treatment modality for wound healing and bone metabolism.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the efficacy of PEMF therapy in promoting bone growth and ulcer healing in patients with Charcot foot ulcers.</AbstractText><AbstractText Label="MATERIALS AND METHODS">This prospective, single-blinded, controlled trial included 34 patients with stage 2 or 3 chronic Charcot foot with ulceration who were randomized into 2 groups. Group A (study group) received PEMF therapy in addition to transcutaneous electrical nerve stimulation (conventional TENS), medical treatment, and standard wound care, while group B (control group) received conventional TENS and the same medical treatment and standard wound care as those in group A, 3 times per week for 3 months. Primary outcomes were assessed with plain radiographs and wound surface area tracing pre-intervention, 6 weeks post-intervention, and 12 weeks post-intervention.</AbstractText><AbstractText Label="RESULTS">No significant differences were evident at baseline analysis. After 6 weeks, both groups showed significant change in Charcot foot signs as well as a reduction in wound surface area (P &lt; .05). In the study group, 23.5% of participants showed complete resolution of Charcot signs (normal appearance), 5.9% progressed to stage 2 (bone sclerosis), and 70.6% remained at stage 1. Regarding wound healing, the study group showed greater reduction in wound surface area, with a median (IQR) of 8.5 cm2 (9.4 cm2-12.2 cm2) compared with 11.5 cm2 (9.4 cm2-15.5 cm2) in the control group. By 12 weeks, 94.1% of the study group showed complete radiological resolution of Charcot signs vs 5.9% in the control group (P &lt; .001). Median wound surface area was significantly reduced in the study group to 0.0 cm&#xb2; (0.0 cm&#xb2;-1.0 cm&#xb2;) compared with 6.6 cm2 (5.7 cm&#xb2;-7.9 cm&#xb2;) in the control group (P &lt; .05), indicating superior healing outcomes with PEMF therapy.</AbstractText><AbstractText Label="CONCLUSION">PEMF therapy is an efficacious adjunctive treatment for Charcot foot ulcers, facilitating both wound healing and bone regeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eltayeb</LastName><ForeName>Norhan Mohamed</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Faculty of Physical Therapy, Cairo University, Cairo, Giza, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelhamid</LastName><ForeName>Marwa Mahdy</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Faculty of Physical Therapy, Cairo University, Cairo, Giza, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yousuf</LastName><ForeName>Hossam Zaghloul</ForeName><Initials>HZ</Initials><AffiliationInfo><Affiliation>Vascular Surgery Department, Kasr Al Ainy Faculty of Medicine, Cairo University; Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abd-Elrashid</LastName><ForeName>Nessrein Afifi</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Faculty of Physical Therapy, Cairo University, Cairo, Giza, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Wounds</MedlineTA><NlmUniqueID>9010276</NlmUniqueID><ISSNLinking>1044-7946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="Y">Wound Healing</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055909" MajorTopicYN="Y">Magnetic Field Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017719" MajorTopicYN="Y">Diabetic Foot</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001177" MajorTopicYN="Y">Arthropathy, Neurogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>10</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40931372</ArticleId><ArticleId IdType="doi">10.25270/wnds/25002</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>